Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Cancer Chemistry

Discovery and characterization of new small-molecule inhibitors of Mcl-1 by high-throughput screening

Zaneta Nikolovska-Coleska, Su Qiu, Jianting long, Chao-Yie Yang, Martha Larsen, York Tomita, Pat Gee, Han Yi, Krzysztof Krajewski, Jeanne Stuckey, Peter Roller and Shaomeng Wang
Zaneta Nikolovska-Coleska
Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, Life Sciences Institute, University of Michigan, Ann Arbor, MI, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, Laboratory of Medicinal Chemistry, National Cancer Institute, National Institutes of Health, Frederick, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Su Qiu
Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, Life Sciences Institute, University of Michigan, Ann Arbor, MI, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, Laboratory of Medicinal Chemistry, National Cancer Institute, National Institutes of Health, Frederick, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianting long
Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, Life Sciences Institute, University of Michigan, Ann Arbor, MI, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, Laboratory of Medicinal Chemistry, National Cancer Institute, National Institutes of Health, Frederick, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chao-Yie Yang
Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, Life Sciences Institute, University of Michigan, Ann Arbor, MI, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, Laboratory of Medicinal Chemistry, National Cancer Institute, National Institutes of Health, Frederick, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martha Larsen
Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, Life Sciences Institute, University of Michigan, Ann Arbor, MI, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, Laboratory of Medicinal Chemistry, National Cancer Institute, National Institutes of Health, Frederick, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
York Tomita
Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, Life Sciences Institute, University of Michigan, Ann Arbor, MI, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, Laboratory of Medicinal Chemistry, National Cancer Institute, National Institutes of Health, Frederick, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pat Gee
Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, Life Sciences Institute, University of Michigan, Ann Arbor, MI, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, Laboratory of Medicinal Chemistry, National Cancer Institute, National Institutes of Health, Frederick, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Han Yi
Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, Life Sciences Institute, University of Michigan, Ann Arbor, MI, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, Laboratory of Medicinal Chemistry, National Cancer Institute, National Institutes of Health, Frederick, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krzysztof Krajewski
Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, Life Sciences Institute, University of Michigan, Ann Arbor, MI, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, Laboratory of Medicinal Chemistry, National Cancer Institute, National Institutes of Health, Frederick, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeanne Stuckey
Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, Life Sciences Institute, University of Michigan, Ann Arbor, MI, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, Laboratory of Medicinal Chemistry, National Cancer Institute, National Institutes of Health, Frederick, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Roller
Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, Life Sciences Institute, University of Michigan, Ann Arbor, MI, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, Laboratory of Medicinal Chemistry, National Cancer Institute, National Institutes of Health, Frederick, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shaomeng Wang
Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, Life Sciences Institute, University of Michigan, Ann Arbor, MI, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, Laboratory of Medicinal Chemistry, National Cancer Institute, National Institutes of Health, Frederick, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2008
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

Abstract

4148

Apoptosis, or programmed cell death, plays a key role in normal tissue homeostasis ensuring a proper balance between cell production and cell loss. Anti-apoptotic Bcl-2-family proteins are key regulators of the apoptotic pathway and their increased expression in human malignancies is associated with disease progression, tumor resistance to chemotherapy, radiation and poor clinical outcome. Recently,a novel Bcl-2/Bcl-xL/Bcl-w inhibitor (ABT-737) has been developed, which is highly potent in killing tumor cells displayinghigh levels of Bcl-2 and dependent upon Bcl-2 forsurvival. However, ABT-737 exhibits a relatively low affinityfor Mcl-1 and is considerably less efficient in killing tumor cellsexpressing high Mcl-1 levels. Several groups provide strong evidence that Mcl-1 is the major factor that causes resistance to ABT-737 in cancer cells derived from diverse solid tumors, and one approach for overcoming this resistance could be the combination of ABT-737 with agentscapable of down-regulating/inhibiting Mcl-1.
Here, we describe a high throughput screening approach that led to the identification of several chemical classes, small molecule Mcl-1 inhibitors. The compounds were characterized in a number of assays including in vitro binding using fluorescence polarization based assay, SPR solution competitive assay, heteronuclear single quantum correlation (HSQC) NMR spectroscopy, pull-down assay, functional assay for cytochrome c and Smac release and a cell-based viability assay with human cancer cells.
The most potent of the inhibitors identified was compound 65, which binds to Mcl-1 protein with IC50 of 0.3 μM, showing >100-fold selectivity over Bcl-xL and 60-fold selectivity over Bcl-2 protein. 15N HSQC spectra conclusively showed that compound 65 interacts with the BH3 domain in Mcl-1 protein and many residues in the BH3 binding groove of Mcl-1 protein were affected by 65. Furthermore, pull-down assay demonstrates that the compound 65 is able in dose dependent manner to disrupt interactions between endogenous Mcl-1 protein and biotin labeled Noxa and Bid BH3 peptides, but not between Bid BH3 peptide and other members of Bcl-2 family (Bcl-xL and Bcl-2). Functional studies showed that compound 65 effectively antagonizes recombinant Mcl-1 protein and promotes release of cytochrome c and Smac from isolated mitochondria. Compound 65 displayed cytotoxicity with IC50 from 3 μM to 8 μM against a number of human cancer cell lines with high level of Mcl-1 protein. Collectively, these data indicate that 65 represents a novel and bone fide small-molecule inhibitor of Mcl-1 and a promising lead compound for further optimization toward developing a new class of anticancer drugs by targeting the Mcl-1 protein.

Footnotes

  • 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 68 (9 Supplement)
May 2008
Volume 68, Issue 9 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Discovery and characterization of new small-molecule inhibitors of Mcl-1 by high-throughput screening
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Discovery and characterization of new small-molecule inhibitors of Mcl-1 by high-throughput screening
Zaneta Nikolovska-Coleska, Su Qiu, Jianting long, Chao-Yie Yang, Martha Larsen, York Tomita, Pat Gee, Han Yi, Krzysztof Krajewski, Jeanne Stuckey, Peter Roller and Shaomeng Wang
Cancer Res May 1 2008 (68) (9 Supplement) 4148;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Discovery and characterization of new small-molecule inhibitors of Mcl-1 by high-throughput screening
Zaneta Nikolovska-Coleska, Su Qiu, Jianting long, Chao-Yie Yang, Martha Larsen, York Tomita, Pat Gee, Han Yi, Krzysztof Krajewski, Jeanne Stuckey, Peter Roller and Shaomeng Wang
Cancer Res May 1 2008 (68) (9 Supplement) 4148;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Cancer Chemistry

  • Abstract 6550: WD105, a novel decursin derivative, showed greater growth inhibition and androgen receptor suppression in LNCaP human prostate cancer cells
  • Abstract 5677: Recurrent transcriptionally active ESR1 fusions render therapeutic vulnerabilities to kinase inhibition in advanced breast cancer
  • Abstract 5681: Design, synthesis and study of small molecules with both AR degradation and AKR1C3 inhibitory activities
Show more Cancer Chemistry

Drug Design and Delivery: Oral Presentations - Proffered Abstracts

  • Precursor-directed biosynthesis of macbecin analogues: generation of non-quinone containing Hsp90 inhibitors and pre-clinical evaluation
  • Design of a novel nanoconjugate based on poly(β-l-malic acid) for intracellular delivery of anti-tumor agents
Show more Drug Design and Delivery: Oral Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement